Med-Fine Capital is a venture capital firm founded in 2014 and headquartered in Shanghai, China, with additional offices in Beijing and Shenzhen. The firm specializes in early-stage and fast-growth investments within the healthcare and life sciences sectors, particularly focusing on the burgeoning healthcare industry in China. Through its strategic investments, Med-Fine Capital aims to support innovative companies that are poised for rapid development and contribute to advancements in healthcare solutions.
Degron Therapeutics is a drug discovery platform. They provide the discovery and development of a new class of targeted protein degradation therapeutics and small molecule molecular glue degrader drugs. Degron Therapies aspires to be a global leader in the discovery and development of small molecule molecular glue degrader (MGD) medicines, a new class of targeted protein degradation therapeutics. Degron has assembled a team of world-class executives and scientific leaders to apply its scientific expertise to the identification and validation of disease targets, particularly those that are inaccessible to conventional small molecule inhibitors, as well as novel selective MGD compounds to address unmet medical needs across all therapeutic areas.
CorrGene
Seed Round in 2022
CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.
Westlake Omics focuses on applying mass spectrometry-based proteomics and other Omics technologies to address pressing clinical needs. It is committed to making breakthroughs in precision medicine and drug R&D with an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data. It was founded in 2020 and is based in Hangzhou, Zhejiang, China.
Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China.
Med-Vision is a heartTM VR developer. They provide hospitals and rehab centers. They also provides post-treatment health management solutions using digitalized gaming features. They provides health care services for mental and psychological health conditions, physical rehabilitation, and cognitive therapies for the elderly.
Epintek develops the biomedical and medical device sectors and offers preclinical research, inspection, and testing, as well as integrated regulatory services, including registration and clinical trial CROs.
Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform, providing first-in-class new molecules consistently and efficiently. Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China.
BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.
Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases.
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
Ranok Therapeutics is a biotechnology company that is developing a novel targeted protein degradation technology to aid in the discovery and development of novel therapeutics. Ranok's TPD technology engages various underlying biological processes and outperforms competing TPD approaches. Ranok's pipeline contains both well-validated and novel drug targets involved in cancer and other diseases with significant unmet medical needs. Ranok is dedicated to developing the next generation of cancer therapies that are both safer and more effective.
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
Suzhou Xinqing Medical Technology Co., Ltd. was founded in 2017 by Dr. Xu Bozhen, a special expert of the National Youth Thousand People Program and a special professor of Suzhou University. He is a high-tech enterprise with the main goal of developing the world's leading in vitro short-term ventricular assist device (in vitro artificial heart). . The core members of the company's entrepreneurial team are the world's top artificial heart engineering technology experts. With years of experience in overseas artificial heart research and development and productization, the company has developed a domestically produced artificial heart with independent intellectual property rights.
Leto Laboratories is a research team that is specialized in platform building for protein re-engineering. The company aims to fill the gaps in the treatment of cancer and rare diseases to benefit patients. Leto Labs has a diversified research team that specializes in platform development for novel protein re-engineering.
Zhuo Dao Medical has a domestic R&D team of rehabilitation robots dedicated to providing world-leading robotic assistive technology and intelligent rehabilitation solutions for clinical rehabilitation. With rich training mode, excellent human-computer interaction and intelligent rehabilitation management system, Zhuo Dao Medical is adapting to the needs of Chinese rehabilitation medicine through continuous accumulation and continuous innovation in the field of rehabilitation engineering, and promoting the rapid development of rehabilitation medicine. .
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.
Cherubs
Series A in 2019
Cherubs is a baby formula milk powder manufacturer.
Beijing Saifu Medical Research Institute Co., Ltd. relies on the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the National Drug Safety Evaluation and Research Center of the State of Beijing to establish strategic partnerships with them to form a combination of technology, capital and enterprise operations. The core members of the company are researchers of the Institute of Materia Medica of the Chinese Academy of Sciences and researchers of the Academy of Military Medical Sciences. They have high scientific research and academic status in the fields of drug research and development and toxicology research, as well as rich drug development, GLP management and technical experience, and build and operate the platform. Provides strong talent and technical support.
Weimi Bio-Tech develops immunofluorescence chromatography products used in inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular testing. They provide comprehensive product solutions and services for medical laboratories.
Eccogene is a clinical stage biopharmaceutical company that provides therapeutic solutions to address unmet medical needs. They offer services in the discovery and development of translational medicine in metabolic and immune-related diseases.
Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.
Julu Medical is a systematic digital rehabilitation technology. Their services include the construction of intensive care rehabilitation system, cardiac rehabilitation systems construction, respiratory rehabilitation system construction, and an elderly cardiopulmonary chronic disease rehabilitation center.
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.
Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases.
Genomeprecision is a molecular diagnostic enterprise integrating R&D, production and sales. It has established “real-time fluorescent quantitative PCR”, “first-generation Sanger sequencing”, “second-generation high-throughput NGS sequencing” and “capillary electrophoresis”. "Fragment Analysis" and "Chemiluminescence CLIA" five molecular diagnostic technology platforms, we will be based on clinical diagnosis and treatment needs to develop molecular diagnostic products based on the above technology platform.
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.
Biosis Healing provides regenerative medicine materials and implantable medical device solutions covering clinical surgery. They offer products for minimally invasive surgery, hernia and abdominal wall surgery, dentistry, neurosurgery, and protective products. The company will continue to create advanced technologies and unique products, as well as promote advanced clinical technology and treatment approaches in collaboration with clinical specialists.
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.